


Slide 1	<h2 style="text-align: center;">Volume of Distribution</h2> <p style="text-align: center;">MBChB 221B</p> <p style="text-align: center;">Dr Stephen Jamieson Dept of Pharmacology and Clinical Pharmacology Auckland Cancer Society Research Centre</p>	
Slide 2	<h2 style="text-align: center;">Learning objectives</h2> <ul style="list-style-type: none"> <li>• Learn the definition of volume of distribution</li> <li>• Understand the physiological determinants of volume of distribution</li> <li>• Realise the limited relevance of plasma protein binding</li> <li>• Be able to describe the time course of drug concentration for one and two compartment pharmacokinetic models</li> <li>• Appreciate the applications of volume concepts to clinical practice</li> </ul>	
Slide 3	<h2 style="text-align: center;">Drug distribution</h2> <ul style="list-style-type: none"> <li>• The reversible movement of drug between body compartments once it has entered the systemic circulation</li> <li>• Influenced by physicochemical properties of drugs <ul style="list-style-type: none"> <li>– Size</li> <li>– Ionisation</li> <li>– Lipophilicity</li> <li>– Plasma protein binding</li> </ul> </li> <li>• Defined by the parameter known as volume of distribution (<math>V_D</math>)</li> </ul>	

Slide 4	<h2 style="text-align: center;">Volume of distribution (<math>V_D</math>)</h2> <p style="text-align: center;"><math>V_D = \frac{\text{amount of drug in the body}}{\text{plasma drug concentration}}</math></p> <ul style="list-style-type: none"> <li>• Determined by: <ul style="list-style-type: none"> <li>– Body mass and composition</li> <li>– Tissue blood flow</li> <li>– Tissue binding (<math>\uparrow V_D</math>)</li> <li>– Plasma protein binding (<math>\downarrow V_D</math>)</li> <li>– Physico-chemical properties of the drug <ul style="list-style-type: none"> <li>• (e.g. size, lipophilicity, ionisation)</li> </ul> </li> <li>– Natural barriers (e.g. blood brain barrier)</li> </ul> </li> </ul>	
Slide 5	<h2 style="text-align: center;">Bathtub model of <math>V_D</math></h2> <div style="text-align: center;">  </div> <p style="text-align: center;"><math>V_D = \text{amount/concentration} = 100 \text{ mg} / 10 \text{ mg/L} = 10 \text{ L}</math></p>	
Slide 6	<h2 style="text-align: center;">Apparent volume of distribution (<math>V_D</math>)</h2> <ul style="list-style-type: none"> <li>• The volume that the drug must be dissolved in to give a concentration equivalent to that found in plasma <ul style="list-style-type: none"> <li>– Gives an indication of distribution out of plasma into tissues</li> <li>– <math>V_D = \text{amount}/\text{conc}_{\text{plasma}}</math></li> </ul> </li> <li>• Not a physiological value</li> <li>• Total body water in 70 kg person <math>\approx 42 \text{ L}</math> <ul style="list-style-type: none"> <li>– Blood volume <math>\approx 5 \text{ L}</math>, plasma <math>\approx 3 \text{ L}</math></li> <li>– Extracellular volume <math>\approx 14 \text{ L}</math></li> <li>– Intracellular volume <math>\approx 28 \text{ L}</math></li> <li>– <math>V_D</math> can exceed <math>42 \text{ L}</math> (e.g. <math>V_D</math> of quinacrine is <math>38000 \text{ L}</math>)</li> </ul> </li> <li>• Drug that rapidly distributes to tissues will have high <math>V_D</math></li> <li>• Drug that stays in plasma will have low <math>V_D</math></li> </ul>	


Slide 7

## Apparent volume of distribution ( $V_D$ )

- Reasons why  $V_D$  is not physiological
  - Binding to tissues
    - Have high  $V_D$
    - e.g. Digoxin binds to  $\text{Na}^+/\text{K}^+$  ATPase
  - Binding to plasma proteins
  - Partitioning into tissues

Slide 8

## Sponge model of $V_D$



$$V_D = \text{amount/concentration} = 100 \text{ mg} / 1 \text{ mg/L} = 100 \text{ L}$$


Slide 9

## Apparent volume of distribution ( $V_D$ )

- Reasons why  $V_D$  is not physiological
  - Binding to tissues
  - Binding to plasma proteins
    - $V_D$  is misleading ("red herring")
      - Bound drug is pharmacologically inactive
    - e.g. warfarin to albumin, lignocaine to  $\alpha_1$ -acid-glycoprotein
  - Partitioning into tissues

Slide 10

## Red Herring Model



$$V_D = \text{dose}/\text{concentration} = 100 \text{ mg} / 100 \text{ mg/L} = 1 \text{ L}$$

Slide 11

## $V_D$ of plasma protein bound drugs

- Many drugs are highly plasma protein bound
  - e.g. warfarin 99% bound to albumin
- Plasma concentrations of warfarin
  - Total = 1 mg/L
  - Bound = 0.99 mg/L
  - Unbound = 0.01 mg/L
- Apparent  $V_D$  for a 10 mg dose of warfarin
  - Total = 10 mg / 1 mg/L = 10 L
  - Unbound = 10 mg / 0.01 mg/L = 1000 L

Slide 12

## Clinical relevance of plasma protein binding

- Approx 50% of drugs are >90% bound to plasma proteins
  - Unbound drug concentrations are responsible for effect
- Impact of alteration of plasma protein binding
  - e.g. by displacement with competing drug or through disease
  - Increased elimination of unbound drug
  - No change in steady state unbound drug concentration
- Only in rare cases can reduction in plasma protein binding due to disease or drug interactions alter clinical response
  - Rapidly cleared IV drugs that are highly plasma protein bound with a narrow therapeutic index

Slide 13	<p><b>Apparent volume of distribution (<math>V_D</math>)</b></p> <ul style="list-style-type: none"> <li>• Reasons why <math>V_D</math> is not physiological <ul style="list-style-type: none"> <li>– Binding to tissues</li> <li>– Binding to plasma proteins</li> <li>– Partitioning into tissues <ul style="list-style-type: none"> <li>• Lipophilic drugs into fat <ul style="list-style-type: none"> <li>– e.g. thiopental</li> <li>– May lead to dosing problems in obese patients where fat content is much higher</li> </ul> </li> <li>• Drug adsorption onto bone <ul style="list-style-type: none"> <li>– e.g. tetracycline, bisphosphonates</li> </ul> </li> </ul> </li> </ul> </li> </ul>	
Slide 14	<p><b>Physiological Basis of <math>V_D</math>: examples</b></p> <ul style="list-style-type: none"> <li>• Warfarin: <math>V_D \approx 10</math> L <ul style="list-style-type: none"> <li>– Less than extracellular fluid, larger than plasma volume</li> <li>– Highly plasma protein bound</li> </ul> </li> <li>• Gentamicin: <math>V_D \approx 16</math> L <ul style="list-style-type: none"> <li>– Similar to extracellular fluid</li> <li>– Highly ionised, low plasma protein binding</li> </ul> </li> </ul>	
Slide 15	<p><b>Physiological Basis of <math>V_D</math>: examples</b></p> <ul style="list-style-type: none"> <li>• Theophylline: <math>V_D \approx 35</math> L <ul style="list-style-type: none"> <li>– Similar to total body water</li> <li>– Non-polar, low plasma protein binding</li> </ul> </li> <li>• Digoxin: <math>V_D \approx 500</math> L <ul style="list-style-type: none"> <li>– <math>\text{Na}^+/\text{K}^+</math> ATPase binding</li> <li>– Muscle, kidney, nervous tissue</li> </ul> </li> </ul>	

Slide 16

## Pharmacokinetic compartments

- Apparent central compartment volume
  - Instantaneous distribution
- Apparent tissue compartment volume
  - Delayed distribution
  - Depends on tissue binding and partition

Slide 17

## One compartment model




Figure adapted from: Holford NHG. Pharmacokinetics and pharmacodynamics: Rational dose selection & the time course of drug action. In: Katzung B, Masters SB, Trevor AJ editors. Basic and Clinical Pharmacology, 13 ed. San Francisco: McGraw-Hill Medical; 2014.

Slide 18

## Two compartment model




Figure adapted from: Holford NHG. Pharmacokinetics and pharmacodynamics: Rational dose selection & the time course of drug action. In: Katzung B, Masters SB, Trevor AJ editors. Basic and Clinical Pharmacology, 13 ed. San Francisco: McGraw-Hill Medical; 2014.

Slide 19	<h2 style="text-align: center;">Distribution rate</h2> <ul style="list-style-type: none"> <li>• Distribution half-life <ul style="list-style-type: none"> <li>– Minutes <ul style="list-style-type: none"> <li>• e.g. thiopental</li> </ul> </li> <li>– Hours <ul style="list-style-type: none"> <li>• e.g. digoxin</li> </ul> </li> <li>– Days <ul style="list-style-type: none"> <li>• e.g. lithium</li> </ul> </li> </ul> </li> </ul>	
Slide 20	<h2 style="text-align: center;">Importance of <math>V_D</math></h2> <ul style="list-style-type: none"> <li>• Can be used to calculate loading dose (LD)</li> <li>• <math>V_D</math> influences <ul style="list-style-type: none"> <li>– Time to reach steady-state</li> <li>– Time for all the drug to be eliminated</li> </ul> </li> <li>• <math>V_D</math> does not influence the steady state conc (<math>C_{ss}</math>)</li> <li>• <math>C_{ss}</math> is determined by <ul style="list-style-type: none"> <li>– Clearance of the drug</li> <li>– Rate of input</li> </ul> </li> </ul>	
Slide 21	<h2 style="text-align: center;">Loading dose (LD)</h2> <ul style="list-style-type: none"> <li>• Initial dose administered to achieve a target concentration rapidly <ul style="list-style-type: none"> <li>– Dependent on <math>V_D</math></li> <li>– Helps to fill bath (<math>V_D</math>) faster to rapidly achieve the target concentration</li> <li>– The bigger the <math>V_D</math> the higher the dose required to achieve target concentration</li> </ul> </li> </ul> <p style="text-align: center;"><b>Loading dose (mg) = <math>V_D</math> (L) x target concentration (mg/L)</b></p> <ul style="list-style-type: none"> <li>• If no loading dose is used, the volume takes time to fill up, so the larger the <math>V_D</math> the longer the time to reach the target conc</li> <li>• Usually given as IV bolus so that target conc is reached quickly, then maintained by IV infusion, but oral loading doses can also be used</li> </ul>	

## Loading dose calculation

- What is the loading dose of theophylline for a patient with asthma to achieve a target concentration of 10 mg/L?
  - $V_D$  of theophylline = 35L
  - Loading dose = 10 mg/L x 35 L = 350 mg
- Maintenance dose was 28 mg/h
  - $CL$  (L/h) x target conc (mg/L)